Alfacell Receives First-Ever Pioneer Award for Mesothelioma Research From Mesothelioma Applied Research Foundation
Tuesday, October 11th, 2005.
Alfacell Corporation today announced that the Company was presented with a “Pioneer Award” from the Mesothelioma Applied Research Foundation (MARF) at its Second International Symposium on Malignant Mesothelioma, held last week in Las Vegas. The Pioneer Award was introduced by MARF this year to honor companies that have made substantial contributions to the field of mesothelioma research.
“It is a great honor to receive one of the first MARF Pioneer Awards,” stated Kuslima Shogen, Chief Executive Officer of Alfacell, who accepted the award on behalf of the Company. “Even greater was the opportunity to meet many patients and others who have lost loved ones to mesothelioma. It was humbling to receive their praise, and inspiring to witness their grace and determination to conquer this terrible disease.”
Shogen concluded, “MARF has done exceptional work in drawing much-needed attention to malignant mesothelioma, an insidious cancer that affects thousands around the world. Through the annual symposium, MARF also provides a unique, interdisciplinary forum for discussion of the scientific and clinical advances in the treatment of this disease. We salute MARF for their efforts, and will continue to work with them on the mission to find a cure.”
In addition to Alfacell, other inaugural Pioneer Award recipients included Eli Lilly, Merck, Biogen Idec and Fujirebio Diagnostics.
For more information about MARF, a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease, visit www.marf.org.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
« Mesothelioma News Main Page.
Most Recent in
Alfacell
- 10/10/08 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
- 05/29/08 - Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint
- 04/02/08 - Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- 01/18/08 - Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
- 01/15/08 - Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Most Recent in
Drug Companies
- 02/18/10 - Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients
- 08/10/09 - Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada
- 04/13/09 - Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
- 12/29/08 - Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
- 10/10/08 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
Most Recent in
Mesothelioma Applied Research Foundation (MARF)
- 02/24/10 - Mesothelioma Applied Research Foundation Funds Eight New Research Projects to Advance Critically-Needed Mesothelioma Treatments
- 09/16/09 - Mesothelioma Awareness Day Expands Since 2005 Founding
- 06/22/09 - Mesothelioma Doctor, Advocate and Volunteers Recognized by the Mesothelioma Applied Research Foundation
- 05/20/09 - 2009 International Symposium on Malignant Mesothelioma: June 25-27
- 06/24/08 - Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients
Most Recent in
Organizations
- 03/15/10 - New NCCN Guidelines™ for Malignant Pleural Mesothelioma Presented at Annual Conference
- 02/24/10 - Mesothelioma Applied Research Foundation Funds Eight New Research Projects to Advance Critically-Needed Mesothelioma Treatments
- 01/29/10 - ADAO’s Sixth Annual International Asbestos Awareness Conference: April 9 – 11, Chicago
- 12/18/09 - Asbestos and Other Hazards Removed from Walpole, Mass. Superfund Site
- 12/12/09 - Statement of Lisa P. Jackson Administrator, U.S. Environmental Protection Agency Legislative Hearing on the Toxic Substances Control Act (TSCA) Senate Committee on Environment and Public Works December 2, 2009
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
